STOCK TITAN
  1. Home
  2. News
  3. MBRX

Moleculin Biotech Inc - MBRX STOCK NEWS

Welcome to our dedicated news page for Moleculin Biotech (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moleculin Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moleculin Biotech's position in the market.

News
Moleculin to Present at the 36th Annual ROTH Conference
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) will have a fireside chat at the 36th Annual ROTH Conference on March 18th. Jonathan Foster, the CFO, will participate, showcasing the company's drug candidates for tumors and viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.22%
Tags
conferences
-
News
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Rhea-AI Summary
Moleculin Biotech, Inc. announces preliminary 2023 year-end Annamycin clinical trials data and 2024 expectations. The data includes MB-106 AML Phase 1B/2 trial preliminary readout and MB-107 STS Lung Mets Phase 1B/2 trial preliminary data. The results show promising intent to treat CR rate and no relapses in MB-106, and extended overall survival in MB-107. The company plans to transition to pivotal Phase 2B/3 clinical studies by the end of 2024 and provides an updated business outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
clinical trial
-
News
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
Rhea-AI Summary
Moleculin Biotech, Inc. (NASDAQ: MBRX) announced a securities purchase agreement for a registered direct offering and concurrent private placement, expected to raise approximately $4.5 million. The offering includes 7,044,836 shares of common stock and unregistered warrants to purchase up to 14,089,672 shares of common stock, priced at $0.64 for the institutional investor and $0.69 for the executive officers and directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
offering
News
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) presents positive preliminary efficacy findings from the European Phase 1B/2 clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia (AML) at the 65th ASH Annual Meeting and Exposition. The CR rate for ITT subjects is 36%, with a durability of up to 8 months, and recruitment in the Phase 1B/2 clinical trial reaches 59%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
clinical trial
-
News
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
Rhea-AI Summary
MBRX: Moleculin Biotech Announces Positive Clinical Trial Data for Next-Generation Anthracycline Annamycin with 38% Complete Response Rate and Zero Cardiotoxicity
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
clinical trial
-
News
Moleculin Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Moleculin Biotech, Inc. (Nasdaq: MBRX) reported $24.6 million in cash with runway estimated into third quarter of 2024. Positive clinical data from Annamycin lead development programs expected to support advancement into pivotal studies for AML and STS in 2024. The company ended the quarter with financial results showing $3.3 million in R&D expense and $2.6 million in general and administrative expense.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
earnings
News
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
Rhea-AI Summary
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its financial results for Q3 2023 on November 13, 2023. The company will also host a conference call and live webcast to discuss the operational and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
conferences earnings
-
News
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Rhea-AI Summary
Moleculin Biotech presented preliminary efficacy findings for Annamycin at the 2023 CTOS Annual Meeting. The drug continues to be 100% non-cardiotoxic and has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of soft tissue sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.07%
Tags
clinical trial
-
News
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Rhea-AI Summary
Moleculin Biotech to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
News
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Rhea-AI Summary
Moleculin Biotech announces Phase 2 trial for Annamycin in AML treatment, with preliminary CR/CRi rate of 33% in Phase 1B portion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
clinical trial
Stock MBRX logo
Moleculin Biotech Inc

Nasdaq:MBRX

MBRX Rankings

N/A Ranked by Market Cap
#4719 Ranked by Stock Gains
N/A Ranked by Dividends

MBRX Stock Data

10.31M
1.93M
4.65%
15.52%
2.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About MBRX

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.